1. Home
  2. VMD vs EOLS Comparison

VMD vs EOLS Comparison

Compare VMD & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

HOLD

Current Price

$8.61

Market Cap

276.0M

Sector

N/A

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$4.49

Market Cap

304.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VMD
EOLS
Founded
2006
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.0M
304.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
VMD
EOLS
Price
$8.61
$4.49
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.40
AVG Volume (30 Days)
164.7K
1.5M
Earning Date
03-09-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
35.92
N/A
EPS
0.34
N/A
Revenue
$254,794,000.00
$285,823,000.00
Revenue This Year
$22.48
$13.70
Revenue Next Year
$22.28
$13.40
P/E Ratio
$25.44
N/A
Revenue Growth
18.89
15.10
52 Week Low
$5.93
$4.41
52 Week High
$8.94
$17.12

Technical Indicators

Market Signals
Indicator
VMD
EOLS
Relative Strength Index (RSI) 81.02 31.31
Support Level $7.82 $4.41
Resistance Level $7.48 $4.99
Average True Range (ATR) 0.23 0.23
MACD 0.13 0.01
Stochastic Oscillator 100.00 11.38

Price Performance

Historical Comparison
VMD
EOLS

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: